PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Hartwell D, Jones J, Baxter L, et al. Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Apr. (Health Technology Assessment, No. 15.17.)

Appendix 7List of excluded studies

The reasons for study exclusion were applied in the order given in the inclusion criteria worksheet (see Appendix 4). Studies may have been excluded on more than one criterion but only the primary reason is given.

Reason for exclusion: study design

  • Aguilera V, Rubin A, Benlloch S, Zamora PA, Ortiz C, Prieto M, et al. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. Liver Transpl. 2008;14:S178.
  • Alberti A, Zehnter E, Lee S, Hadziyannis S, Zeuzem S, Rizzetto M, et al. Sustained virological response rates with peginterferon alpha-2a (40 kd) (PEGASYS®) plus ribavirin (COPEGUS®) in randomised controlled clinical trials are replicated in the clinical practice setting. J Hepatol. 2007;46(Suppl. 1)
  • Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008;28:397–404. [PubMed: 18549461]
  • Berg C, Goncales FL Jr, Bernstein DE, Sette H Jr, Rasenack J, Diago M, et al. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat. 2006;13:435–40. [PubMed: 16792536]
  • Cervoni J, Richou C, Thevenot T, Di Martino V. Shortened course of therapy for chronic hepatitis C genotype 1 (G1) patients developing rapid virological response (RVR): meta-analysis of randomized controlled trials (RCTs) J Hepatol. 2009;50(Suppl. 1):220–1.
  • Condat B. Peginterferon alpha-2b plus ribavirine compared with interferon alpha-2 and ribavirine for the treatment of chronic hepatitis C: a randomized trial. Hepatogastoenterology. 2002;9:141–2.
  • Derbala M, Amer A, Bener A, Lopez AC, Omar M, El GM. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat. 2005;12:380–5. [PubMed: 15985008]
  • Di Martino V, Richou C, Thevenot T, Sanchez-Tapias JM, Ferenci P. Modulations of peginterferon plus ribavirin duration according to HCV-genotype and virologic response at w4 and w12: meta-analyses of RCTs with individual data. Hepatology. 2008;48:404A.
  • Grewal AS, Choudhary A, Bechtold ML, Puli SR, Othman MO, Roy PK. Peginterferon and ribavirin for treatment of hepatitis C and HIV co-infection: a meta-analysis of randomized controlled trials. Gastroenterology. 2008;134(Suppl. 1)
  • Mohsen A, Norris S. Hepatitis C (chronic) Clin Evid Handbook. 2007:262–4.
  • Moreno L, Quereda C, Moreno A, Perez-Elias MJ, Antela A, Casado JL, et al. Pegylated interferon alpha 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS. 2004;18:67–73. [PubMed: 15090831]
  • Nunez M, Marino A, Miralles C, Berdun MA, Sola J, Hernandez-Burruezo JJ, et al. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients. J Acquir Immune Defic Syndr. 2007;45:439–44. [PubMed: 17468669]
  • Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972–82. [PubMed: 17725413]
  • Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40kd) plus ribavirin in patients with HIV/hepatitis C virus co-infection. J Acquir Immune Defic Syndr. 2008;47:36–49. [PubMed: 18156990]
  • Perronne C, Carrat F, Banisadr F, Morand P, Lunel F, Rosenthal E, et al. ANRS HC02-Ribavic: a randomized controlled trial of pegylated interferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin as primary treatment of chronic hepatitis C in HIV co-infected patients. Hepatology. 2002;36:283A.
  • Poynard T, Schiff E, Terg R, Moreno Otero R, Flamm S, Schmidt W, et al. Sustained viral response (SVR) is dependent on baseline characteristics in the re-treatment of previous alfa interferon/ribavirin (I/R) nonresponders (NR): final results from the EPIC3 program. 43rd Annual Meeting of the European Association for the Study of the Liver (EASL); 23–27 April 2008; Milan, Italy.
  • Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, Fernandez-Carbia A, Gonzalez-Lassalle E, Salgado-Mercado R, et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV co-infected patients who failed previous IFN based therapy. J Clin Virol. 2007;38:32–8. [PubMed: 17064957]
  • Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451–60. [PubMed: 16890599]
  • Sarrazin C, Schwendy S, Moller B, Dikopoulos N, Buggisch P, Encke J, et al. Individualized treatment duration with peginterferon-alfa-2B and ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with undetectable HCV-RNA early during therapy (INDIV-2 STUDY) J Hepatol. 2009;50(Suppl. 1):236.
  • Schiff E, Poordad F, Jacobson I, Flamm S, Bacon B, Lawitz E, et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness. J Hepatol. 2008;48(Suppl. 2):46.
  • Shiffman ML, Mansbach H, Hammond J, O'Neill M. The effect of complete and partial response at week 12 on sustained virologic response: results from controlled trials in naive HCV genotype 1 patients treated with pegylated interferon and ribavirin. Hepatology. 2007;46(Suppl.):824A–5A.
  • Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV co-infection: a research synthesis (Cochrane provisional abstract) J Viral Hepat. 2007;14:239–48. [PubMed: 17381715]
  • Slavenburg S, Weggelaar I, van Oijen MGH, Drenth JPH. Optimal length of antiviral therapy in patients with hepatitis C virus genotype 2 and 3: a meta-analysis. EASL 44th Annual Meeting; 22–26 April 2009; Copenhagen, Denmark.
  • Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschenes M, Marotta PJ, et al. Retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol. 2009;23:180–4. [PMC free article: PMC2694653] [PubMed: 19319382]
  • Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomized, controlled, open-label study of peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 vs. 24 weeks in patients with genotype 2 hepatitis C infection. Hepatology. 2006;44:267A.
  • Zoulim F. Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment. Gastroenterol Clin Biol. 2002;26:225–230. [PubMed: 12180293]

Reason for exclusion: population

  • Berak H, Kolakowska-Rzadzka A, Wasilewski M, Kowalska J, Stanczak JJ, Bardadin K, et al. Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2b vs alfa 2b treatment of patients with chronic hepatitis C infected with non 2/3 genotypes: final analysis. J Hepatol. 2007;46(Suppl. 1):217–18.
  • Brady DE, An JW, Lawitz EJ, Harrison S. Does induction pegylated interferon alfa-2b in combination with ribavirin enhance the sustained response rates in patients with genotype 1 and 4 chronic hepatitis C? Results from a prospective, randomized, multi-center, open-label treatment study. Hepatology. 2008;48:402A.
  • Brandao C, Barone A, Carrilho F, Silva A, Patelli M, Caramori C, et al. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. J Viral Hepat. 2006;13:552–9. [PubMed: 16901286]
  • Dalgard O, Bjoro K, Ring-Larsen H, Verbaan H. Peginterferon alpha-2b and ribavirin for 14 or 24 weeks in patients with HCV genotype 2 or 3 and rapid virological response. The North-C trial. J Hepatol. 2007;46(Suppl. 1):S57.
  • Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008;47:35–42. [PubMed: 17975791]
  • Diago M, Crespo J, Olveira A, Perez R, Barcena R, Sanchez-Tapias JM, et al. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther. 2007;26:1131–8. [PubMed: 17894655]
  • Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology. 2006;44:1675–84. [PubMed: 17133499]
  • Ferenci P, Laferl H, Scherzer TM, Maieron A, Gschwantler M, Brunner H, et al. Customizing treatment with peginterferon alfa-2a (40 kd) (PEGASYS®) plus ribavirin (COPEGUS®) in patients with HCV genotype 1 or 4 infection. Interim results of a prospective randomized trial. Hepatology. 2006;44:336A.
  • Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007;46:971–81. [PubMed: 17894303]
  • Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005;54:858–66. [PMC free article: PMC1774522] [PubMed: 15888797]
  • Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology. 2007;46:1732–40. [PubMed: 17943989]
  • Lagging M, Pedersen C, Rauning BM, Färkkilä M, Langeland N, Mørch K, et al. Comparison of peginterferon alpha-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3: the Nordynamic trial. J Hepatol. 2007;46(Suppl. 1):229.
  • Lagging M, Pedersen C, Rauning BM, Färkkilä M, Langeland N, Mørch K, et al. Peginterferon alfa-2A and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3: the Nordynamic trial. Hepatology. 2007;46(Suppl. 1):815A–16A.
  • Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008;47:1837–45. [PubMed: 18454508]
  • Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609–17. [PubMed: 15972867]
  • Mangia A, Minerva N, Carretta V, Bacca D, Ricci GL, Vinelli F, et al. Predictors of rapid virologic response (RVR) in HCV genotype 1 chronic infected patients: results of a randomized controlled trial on individualized treatment. Hepatology. 2006;44(Suppl. 1):606A–7A.
  • Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, et al. Reduced dose and duration of peginterferon alfa-2B + weight-based ribavirin in European and Asian genotype 2 and 3 chronic hepatitis C patients (REDD 2/3 trial) J Hepatol. 2009;50(Suppl. 1):59.
  • Mathew A, Peiffer LP, Rhoades K, McGarrity T. Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment. Dig Dis Sci. 2006;51:1956–61. [PubMed: 17004124]
  • Mecenate F, Barbaro G, Pellicelli A, Barlattani A, Mazzoni E, Bonaventura M, et al. Comparison of peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2 or 3: the CLEO trial. Hepatology. 2007;46(Suppl. 1):828A.
  • Rumi M, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Russo A, et al. Randomized study comparing peginterferon-alfa2a plus ribavirin and peginterferon-alfa2b plus ribavirin in naive patients with chronic hepatitis c: final results of the Milan safety tolerability (MIST) study. Hepatology. 2008;48:404A.
  • Sakai T, Iino S, Omata M, Kiyosawa K, Kumada H. Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive Japanese chronic hepatitis C patients: efficacy and safety of a randomised, double-blind, multicentre, phase III trial. J Gastroenterol Hepatol. 2006;21:A25.
  • Shiffman ML, Nelson DR, Hooper G, Messinger D, Zeuzem S. HCV Patients with genotype 2 or 3 who do not achieve a rapid virologic response (RVR) with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) are not easy to treat: an analysis of non-RVR patients from the ACCELERATE study. Hepatology. 2007;46(Suppl. 1):309A–10A.
  • Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007;357:124–34. [PubMed: 17625124]
  • Shiha G, Abdel KE, Abbas B, Elshennawy H, Zalata KH. Sustained virological response of peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus genotype 4. J Hepatol. 2007;46(Suppl. 1):215.
  • Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns M, et al. Clinical effectiveness and cost-effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics. 2009;27:341–54. [PubMed: 19485429]
  • Tang KH, Herrmann E, Pachiadakis I, Paulon E, Tatman N, Zeuzem S, et al. Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin. Aliment Pharmacol Ther. 2008;27:810–19. [PubMed: 18221408]
  • Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response. Liver Int. 2009;29:120–5. [PubMed: 18384519]
  • Tsubota A, Satoh K, Aizawa M, Takamatsu S, Namiki Y, Ohkusa T, et al. Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study. World J Gastroenterol. 2008;14:7220–4. [PMC free article: PMC2776880] [PubMed: 19084937]

Reason for exclusion: intervention

  • Behler CM, Vittinghoff E, Lin F, Chung RT, Peters MG, Robbins GK, et al. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis. 2007;44:1375–83. [PMC free article: PMC4075655] [PubMed: 17443478]
  • Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, et al. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther. 2005;10:309–17. [PubMed: 15865225]
  • Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839–48. [PubMed: 15598915]
  • Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-co-infected persons. N Engl J Med. 2004;351:451–9. [PMC free article: PMC4113392] [PubMed: 15282352]
  • Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-co-infected patients. J Viral Hepat. 2007;14:228–38. [PubMed: 17381714]
  • Dalgard O, Bjoro K, Ring-Larsen H, Verbaan H, North C. Is sustained virological response to HCV treatment associated with a clinical important improvement in vitality? J Hepatol. 2008;48(Suppl. 2):272.
  • De Compadri P, Koleva D, Mangia A, Motterlini N, Garattini L. Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus. J Med Economics. 2008;11:151–63. [PubMed: 19450116]
  • Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359:2429–41. [PMC free article: PMC2606037] [PubMed: 19052125]
  • Fuster D, Planas R, Gonzalez J, Force L, Cervantes M, Vilaro J, et al. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV co-infected patients with no early virological response. Antivir Ther. 2006;11:473–82. [PubMed: 16856621]
  • Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, et al. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS. 2006;20:345–51. [PMC free article: PMC4060610] [PubMed: 16439867]
  • Haque M, Yoshida EM. Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Ann Hepatol. 2009;8:78–9. [PubMed: 19221541]
  • Hezode C, Foucher J, Bronowicki JP, Leroy V, Tran A, Larrey DG, et al. Efficacy and safety of an intensified regimen of pegylated interferon alfa-2A plus ribavirin in HCV genotype 1-infected patients who did not respond to a prior standard regimen of pegylated interferon alfa-2A plus ribavirin: an interim analysis of the multicentric, randomized, controlled SYREN trial. Hepatology. 2008;48(Suppl.):1148A–9A.
  • Jensen D, Craxi A, Brandao-Mello C, Di Bisceglie A, Andreone P, Freilich B, et al. Identifying patients with a high likelihood of achieving an SVR following re-treatment with peginterferon alfa-2a (40 Kd) plus ribavirin: use of positive prognostic factors (PPFs) J Hepatol. 2009;50(Suppl. 1):228.
  • Jensen DM, Marcellin P, Freilich B, Andreone P, DiBisceglie A, Brandao-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha 2b: a randomized trial. Ann Intern Med. 2009;150:528–40. [PubMed: 19380853]
  • Kallinowski B, Stein K, Boecher W, Goeser T, Spengler U, Link R, et al. Comparison of a shortened ribavirin treatment vs a 24 week standard combination therapy in HCV infected patients with genotype 2/3. J Hepatol. 2007;46(Suppl. 1):228–9.
  • Khalili M, Bernstein D, Lentz E, Barylski C, Hoffman-Terry M. Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV co-infection: partially blinded, randomized multicenter trial. Dig Dis Sci. 2005;50:1148–55. [PubMed: 15986873]
  • Kim AI, Dorn A, Bouajram R, Saab S. The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis. HIV Med. 2007;8:312–21. [PubMed: 17561878]
  • Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27–36. [PubMed: 15316335]
  • Laguno M, Larrousse M, Murillas J, Blanco JL, Leon A, Milinkovic A, et al. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. J Acquir Immune Defic Syndr. 2007;44:174–8. [PubMed: 17106276]
  • Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49:22–31. [PubMed: 19085908]
  • Lissen E, Clumeck N, Sola R, Mendes-Correa M, Montaner J, Nelson M, et al. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS. 2006;20:2175–81. [PubMed: 17086057]
  • Marcellin P, Freilich B, Andreone P, DiBisceglie A, Brandao CE, Reddy KR, et al. HCV-RNA status at week 12 of treatment with peginterferon alfa2a/RBV predicts SVR in patients with prior non-response to pegylated interferon alfa-2b/RBV: results from repeat study. J Hepatol. 2008;48(Suppl. 2):301.
  • Marcellin P, Freilich B, Andreone P, DiBisceglie A, Brandao CE, Reddy KR, et al. Type of response to prior pegylated interferon alfa-2B (12KD)/RBV predicts subsequent response to retreatment with peginterferon alfa-2A (40 Kd)/RBV. J Hepatol. 2008;48(Suppl. 2):306.
  • Puoti M, Zanini B, De Luca A, Quinzan GP, Allegri R, Bruno R, et al. Results of a randomized controlled trial on the impact of prolonged combination anti-HCV treatment in HIV/HCV co-infected patients. J Hepatol. 2008;48(Suppl. 2):309.
  • Rodriguez-Torres M, Torriani F, Rockstroh J, DePamphilis J, Carosi G, Dieterich DT. Patients co-infected with HCV and HIV who achieve an RVR (HCV RNA < 50 IU/ml at week 4) or cEVR (HCV RNA < 50 IU/ml at week 12) have similar rates of SVR to monoinfected patients treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) Hepatology. 2007;46(Suppl. 1):814A.
  • Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–50. [PubMed: 15282351]
  • Zhao S, Cheng D, Liu E, Yu H, Yang H, Xue X, et al. Peginterferon vs. interferon in the treatment of different HCV genotype infections in HIV patients. Eur J Clin Microbiol Infect Dis. 2008;27:1183–92. [PubMed: 18560911]

Reason for exclusion: outcomes

  • Shiffman ML, Morishima C, Lindsay KL, Hoefs JC, Dienstag JL, Szabo G, et al. Suppression of serum HCV RNA levels during maintenance peginterferon (PEGIFN) alfa-2a therapy and clinical outcomes in the HALT-C trial. J Hepatol. 2008;48(Suppl. 2):62.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Cover of Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation
Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.17.
Hartwell D, Jones J, Baxter L, et al.
Southampton (UK): NIHR Journals Library; 2011 Apr.

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...